<DOC>
	<DOCNO>NCT01426854</DOCNO>
	<brief_summary>The purpose study demonstrate Nepafenac Ophthalmic Suspension , 0.1 % superior Nepafenac Vehicle ( placebo ) prevention treatment ocular inflammation pain associate cataract surgery Chinese subject .</brief_summary>
	<brief_title>Nepafenac Compared Placebo Ocular Pain Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Adult Chinese subject , 18 year age old , either sex cataract , expect undergo cataract extraction implantation posterior chamber intraocular lens ; Study eye subject , opinion Investigator , improvement bestcorrected visual acuity surgery ; Subjects able understand sign inform consent approve Independent Ethics Committee ; Other protocoldefined inclusion criterion may apply . Use topical ocular systemic steroid within 14 day prior surgery ; Use topical ocular systemic nonsteroidal antiinflammatory drug within 7 day surgery , except allow daily dose baby aspirin ( 81 mg ) ; Subjects plan cataract surgery fellow , nonstudy eye prior 14 day postoperative study visit ; Any intraocular inflammation ocular pain great Grade 0 study eye present baseline slitlamp exam ; Women childbearing potential ( surgically sterilize post menopausal ) may participate study follow condition exist : breast feeding ; positive urine pregnancy test baseline ; willing undergo urine pregnancy test upon exit study ; intend become pregnant duration study ; , agree use adequate birth control method duration study . Any abnormality prevents reliable tonometry ; Planned multiple procedure cataract/IOL implantation surgery ; Lens pseudoexfoliation syndrome glaucoma zonular compromise ; Previous ocular trauma operative eye ; A history chronic recurrent inflammatory eye disease ; Ocular infection ocular pain ; Proliferative diabetic retinopathy ; Uncontrolled diabetes mellitus ; Congenital ocular anomaly ; Iris atrophy operative eye ; A nonfunctional fellow eye ; Use investigational intraocular lens ; Participation clinical study within 30 day surgery ; Known suspect allergy hypersensitivity nonsteroidal antiinflammatory agent , component study medication ; Subjects know bleeding tendency , receive medication may prolong bleeding time , may enrol physician 's discretion ; continuation previous therapy subject leave judgment physician ; The fellow eye individual currently previously enrol study ; Subjects use topical ophthalmic prostaglandin ; Subjects , opinion investigator , might increase risk complication topical NSAIDs ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cataract Surgery</keyword>
	<keyword>Anti-ocular Inflammation</keyword>
	<keyword>Anti-ocular Pain</keyword>
</DOC>